Strengthened leadership boosts support to Industry Partners

As part of its strategic plans to support global pharmaceutical companies in meeting their Chemistry, Manufacturing and Controls (CMC) demands, CatSci has strengthened its senior leadership team with key appointments.

Dr Jerome Théobald, who has become Chief Operating Officer, brings almost 30 years’ experience in the pharmaceutical market. Having held positions as CEO and COO for several life science companies he will play a key role in supporting and propelling the growth of CatSci’s core business, including the development of GMP capabilities and the expansion of its offerings in oligonucleotides, material science, pre-formulation and analytical development.

Jaana Grüter has joined the Board as Investment Director. A managing director at Keensight Capital she will be influential in accelerating the business development strategy which will help businesses unlock their full potential through investment.

Rob Crook brings over 28 years of pharma expertise across the CMC landscape to his new role as Director of Chemical Sciences; his will build on strategic value to its customers’ working closely with CatSci’s formulation, measurement and material science functions.

The new Director of Pharmaceutical Development, Dr Gary Parsons has notable expertise in marketing of inhaled products having worked across all phases of development, from lead optimisation to initial commercial supply in support of the creation of GSK’s Ellipta portfolio of inhaled medicines. His focus will be on integration of API material science into dosage form design, involving customers in decision-making early in the development process.

Jenn Clark has become Head of Customer Acquisition; with over 20 years of experience in the pharmaceutical industry, she has held several key strategic roles in businesses recognised for customer excellence. She has specific experience in driving partnerships with companies in both development programmes as well as commercialisation, particularly within the inhalation field.

Dr Raj Gill has taken responsibility as Head of Scientific Operations; with experience spanning  drug product development through to delivering business operations, she will lead CatSci’s Scientific Operations team in the next phase of its evolution. With nearly 25 years in the pharmaceutical industry, she is focused on providing both scientific and operational leadership to successfully deliver projects and achieve business targets.

This year has been highly productive for the company which has received significant investment from Keensight Capital to support the continued growth of CatSci’s core business via capability and site expansion, as well as the development of GMP capabilities and the expansion of its offering in oligonucleotide services. Another exciting new development has been the opening of a dedicated laboratory, including a powder handling isolator, to enable operation at OEB-5 (OEL 0.1 – 1.0 µg/m3). Due to high demand, this capability will be available to support all customers and new projects from the beginning of 2023, the company said.

More information online